Evolving the Unwearable Collection
Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™
Search
FDA Approves OFEV® (nintedanib) to Treat IPF | BI US
Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).
Supplier Diversity
Supplier Diversity
Boehringer Ingelheim Academy Video 2023
Video providing an overview of Boehringer Ingelheim’s Academy initiative and how this networking program facilitates conversations across the innovation community.
Community Guidelines
We welcome your comments and posts and look forward to a dialogue about science & health and our commitment to bring More Health to people around the world.
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
Social Impact | COVID-19 | Boehringer Ingelheim US
Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.
Corporate Social Responsibility | Boehringer Ingelheim US
Boehringer Ingelheim has a strong and longstanding commitment to improving the health of people and animals, both around the world and in local communities.
Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners
Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US
American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US
Boehringer Ingelheim to donate 75,000 doses of IMRAB® vaccine to the Global Alliance for Rabies Control through shots for Good Initiative.
Grass Roots Innovation Overview
Video providing an overview of the Grass Roots Innovation Program and how the activities support the next generation of life-science innovators and entrepreneurs
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Sunshine Act Compliance
Sunshine Act Compliance
Boehringer Ingelheim: Discover the app set to transform animal care in rural India
Learn about the app set to transform animal care in rural India. Women will be empowered and goat welfare will be promoted. From idea to app!
BI Cares Financial Contributions Program: Strengthening Communities
BI Cares Financial Contributions Program: Strengthening Communities
Business Resource Groups at Boehringer Ingelheim
Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.
Our Commitment
Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d
Yankees Legend Bernie Williams and Celebrity Vocal Coach Eric Vetro Harness the Power of Music with Tune In To Lung Health® for Interstitial Lung Disease Awareness
An extension of Boehringer Ingelheim’s Breathless® campaign, Tune In To Lung Health explores how music and breathing may help motivate, inspire, and support people living with interstitial lung disease (ILD) Program resources introduced during September’s
OFEV® (nintedanib) Now Available in the United States
OFEV® (nintedanib) Now Available in the United States
Biosimilar Candidate to Humira® Accepted For Review | BI US
Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis